Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer.
Abstract | INTRODUCTION: The PENELOPE trial evaluated pertuzumab added to chemotherapy for biomarker-selected platinum-resistant ovarian cancer. As previously reported, pertuzumab did not statistically significantly improve progression-free survival (primary end point: HR 0.74, 95% CI 0.50 to 1.11), although results in the paclitaxel and gemcitabine cohorts suggested activity. Here, we report final overall survival and patient-reported outcomes. PATIENTS AND METHODS: RESULTS: At database lock (June 9, 2016), 130 (83%) of 156 randomized patients had died. Median follow-up was 27 months in the pertuzumab arm versus 26 months in the control arm. In the intent-to-treat population there was no overall survival difference between treatment arms (stratified HR 0.90, 95% CI 0.61 to 1.32; p=0.60). Results in subgroups defined by stratification factors indicated heterogeneity similar to previous progression-free survival results. Updated safety was similar to previously published results. Compliance with patient-reported outcomes questionnaire completion was >75% for all validated patient-reported outcomes measures. Pertuzumab demonstrated neither beneficial nor detrimental effects on patient-reported outcomes compared with placebo, except for increased diarrhea symptoms. DISCUSSION: Consistent with the primary results, adding pertuzumab to chemotherapy for low tumor HER3 mRNA-expressing platinum-resistant ovarian cancer did not improve overall survival, but showed trends in some cohorts. Except for increased diarrhea symptoms, pertuzumab had no impact on patient-reported outcomes. ClinicalTrials.gov: ClinicalTrials.gov: NCT01684878.
|
Authors | Domenica Lorusso, Felix Hilpert, Antonio González Martin, Joern Rau, Petronella Ottevanger, Elfriede Greimel, Hans-Joachim Lück, Frédéric Selle, Nicoletta Colombo, Judith R Kroep, Mansoor R Mirza, Regina Berger, Beatriz Pardo, Eva-Maria Grischke, Dominique Berton-Rigaud, Jeronimo Martinez-Garcia, Ignace Vergote, Andrés Redondo, Andrés Cardona, Lydie Bastière-Truchot, Andreas du Bois, Christian Kurzeder, PENELOPE trial investigators |
Journal | International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
(Int J Gynecol Cancer)
Vol. 29
Issue 7
Pg. 1141-1147
(09 2019)
ISSN: 1525-1438 [Electronic] England |
PMID | 31420414
(Publication Type: Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | © IGCS and ESGO 2019. No commercial re-use. See rights and permissions. Published by BMJ. |
Chemical References |
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents, Immunological
- RNA, Messenger
- Deoxycytidine
- Topotecan
- ERBB3 protein, human
- Receptor, ErbB-3
- pertuzumab
- Paclitaxel
- Gemcitabine
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal, Humanized
(administration & dosage)
- Antineoplastic Agents, Immunological
(administration & dosage)
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Carcinoma, Ovarian Epithelial
(drug therapy, enzymology, genetics)
- Deoxycytidine
(administration & dosage, analogs & derivatives)
- Double-Blind Method
- Drug Resistance, Neoplasm
- Female
- Humans
- Middle Aged
- Ovarian Neoplasms
(drug therapy, enzymology, genetics)
- Paclitaxel
(administration & dosage)
- Patient Reported Outcome Measures
- Progression-Free Survival
- RNA, Messenger
(biosynthesis, genetics)
- Receptor, ErbB-3
(biosynthesis, genetics)
- Topotecan
(administration & dosage)
- Gemcitabine
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|